

PRESS RELEASE

Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie's 16th Annual Nordic Healthcare Conference

Lund, Sweden, 13 November, 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a fireside chat with Farzin Haque, Biotechnology Equity Research Analyst, Jefferies, at the Jefferies Healthcare Conference in London, on Monday 17 November, 2025. Aguiar-Lucander will also present Hansa Biopharma at DNB Carnegie's 16th Annual Nordic Healthcare Conference in Oslo, Tuesday 25 November, 2025.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: Jefferies Global Healthcare Conference – London, Hansa Biopharma Fireside Chat

Date, Time, and Place: Monday 17 November, 15:00-15:25 PM GMT, Waldorf Hilton, London.

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Moderator: Farzin Haque, Biotechnology Equity Research Analyst, Jefferies

Webcast: [Jefferies Webcast Link](#)

Event: DNB Carnegie: 16th Annual Nordic Healthcare Conference, Hansa Biopharma Presentation

Date, Time, and Place: Tuesday 25 November, 12:30-12:50 CET, Oslo.

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on [LinkedIn](#).

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.